Literature DB >> 19095951

Expression pattern and subcellular localization of human papillomavirus minor capsid protein L2.

Zhenhua Lin1, Anna V Yemelyanova, Ratish Gambhira, Subhashini Jagu, Craig Meyers, Reinhard Kirnbauer, Brigitte M Ronnett, Patti E Gravitt, Richard B S Roden.   

Abstract

The expression pattern of human papillomavirus (HPV) capsid antigen L2 is poorly described, and the significance of its localization with both promyelocytic leukemia protein (PML) and Daxx in a subnuclear domain, nuclear domain 10 (ND-10), when ectopically expressed in tissue culture cells is controversial. To address whether ND-10 localization of L2 occurs in natural cervical lesions, we used a HPV16 and HPV18 L2-specific monoclonal antibody (RG-1), in addition to rabbit antiserum to HPV6 L2, to localize L2. Immunohistochemical staining with RG-1 produced diffuse staining in the nuclei of some cells located within the superficial epithelial layers in eight of nine cases of HPV16/18(+) cervical intraepithelial neoplasia grade 1 (CIN1); however, no staining was observed in HPV16/18(+) high-grade CIN (0 of 8 cases), normal cervical epithelium (0 of 20 cases), cervical squamous cell carcinoma (0 of 102 cases), adenocarcinoma (0 of 51 cases), or adenosquamous carcinoma (0 of 6 cases). HPV16/18(+) cervical lesions that express L2 exhibit higher HPV16/18 genome copies per cell compared with those that do not positively stain with RG-1 (P = 0.04). RG-1 staining of HeLa cells transfected with L2 expression constructs was frequently concentrated in the ND-10, particularly in cells expressing high levels of L2, and co-localized with the cellular markers of ND-10, PML, and Daxx. In contrast, L2 was primarily diffuse within the nucleus and distinct from ND-10 as defined by PML immunofluorescent staining in CIN lesions, condylomata, and HPV16-transduced organotypic cultures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19095951      PMCID: PMC2631326          DOI: 10.2353/ajpath.2009.080588

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Propagation, infection, and neutralization of authentic HPV16 virus.

Authors:  Margaret E McLaughlin-Drubin; Neil D Christensen; Craig Meyers
Journal:  Virology       Date:  2004-05-01       Impact factor: 3.616

2.  Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70.

Authors:  Luise Florin; Katrin A Becker; Cornelia Sapp; Carsten Lambert; Hüseyin Sirma; Martin Müller; Rolf E Streeck; Martin Sapp
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 3.  Intrinsic immunity: a front-line defense against viral attack.

Authors:  Paul D Bieniasz
Journal:  Nat Immunol       Date:  2004-11       Impact factor: 25.606

4.  Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames.

Authors:  J M Firzlaff; N B Kiviat; A M Beckmann; S A Jenison; D A Galloway
Journal:  Virology       Date:  1988-06       Impact factor: 3.616

5.  [Ultrastructural observation of human papillomavirus particles in the uterine cervix intraepithelial neoplasia].

Authors:  S Sato; H Chiba; K Shikano; M Horiguchi; Y Wada; A Yajima; T Okagaki
Journal:  Gan No Rinsho       Date:  1988-07

6.  Coexpression of the human papillomavirus type 16 E4 and L1 open reading frames in early cervical neoplasia.

Authors:  C P Crum; S Barber; M Symbula; K Snyder; A M Saleh; J K Roche
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

7.  Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.

Authors:  Patricia M Day; Carl C Baker; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

8.  PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication.

Authors:  Asne Jul-Larsen; Therese Visted; Bård Ove Karlsen; Christine Hanssen Rinaldo; Rolf Bjerkvig; Per Eystein Lønning; Stig Ove Bøe
Journal:  Exp Cell Res       Date:  2004-08-01       Impact factor: 3.905

9.  Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles.

Authors:  Katrin A Becker; Luise Florin; Cornelia Sapp; Gerd G Maul; Martin Sapp
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Human papillomavirus type 16 infection of the cervix: a comparison of differing DNA detection modes and the use of monoclonal antibodies against the major capsid protein.

Authors:  C J Lacey; M Wells; R I Macdermott; P E Gibson
Journal:  Genitourin Med       Date:  1991-04
View more
  13 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

Review 2.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

3.  The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic.

Authors:  Shahan Mamoor; Zeynep Onder; Balasubramanyam Karanam; Kihyuck Kwak; Jennifer Bordeaux; Lauren Crosby; Richard B S Roden; Junona Moroianu
Journal:  Virology       Date:  2011-12-06       Impact factor: 3.616

4.  The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs.

Authors:  Marc A Schneider; Konstanze D Scheffer; Timo Bund; Fatima Boukhallouk; Carsten Lambert; Cristina Cotarelo; Gert O Pflugfelder; Luise Florin; Gilles A Spoden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

5.  The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis.

Authors:  Elena Wüstenhagen; Laura Hampe; Fatima Boukhallouk; Marc A Schneider; Gilles A Spoden; Inka Negwer; Kaloian Koynov; W Martin Kast; Luise Florin
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

Review 6.  L2, the minor capsid protein of papillomavirus.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Virology       Date:  2013-05-17       Impact factor: 3.616

Review 7.  Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.

Authors:  Balasubramanyam Karanam; Subhashini Jagu; Warner K Huh; Richard B S Roden
Journal:  Immunol Cell Biol       Date:  2009 May-Jun       Impact factor: 5.126

8.  Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.

Authors:  Joshua W Wang; Wai Hong Wu; Tsui-Chin Huang; Margaret Wong; Kihyuck Kwak; Keiko Ozato; Chien-Fu Hung; Richard B S Roden
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

9.  Immunohistochemical detection of human papillomavirus capsid proteins L1 and L2 in squamous intraepithelial lesions: potential utility in diagnosis and management.

Authors:  Anna Yemelyanova; Patti E Gravitt; Brigitte M Ronnett; Ann F Rositch; Aleksandra Ogurtsova; Jeffrey Seidman; Richard B S Roden
Journal:  Mod Pathol       Date:  2012-09-21       Impact factor: 7.842

10.  Distribution and location of Daxx in cervical epithelial cells with high risk human papillomavirus positive.

Authors:  Shuang-yang Tang; Le Li; Yao-lin Li; An-yuan Liu; Min-jun Yu; Yan-ping Wan
Journal:  Diagn Pathol       Date:  2014-01-08       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.